KPV

Immune support Research compound (not approved for human use)

Tripeptide fragment of α-MSH · also known as Lys-Pro-Val, α-MSH (11-13)

For reference only — not medical advice. Figures are commonly reported values compiled from published sources and may be wrong or out of date. Many compounds listed are not approved for human use. Talk to a licensed clinician before using any compound.

KPV (lysine-proline-valine) is a short fragment of the hormone alpha-melanocyte-stimulating hormone that keeps anti-inflammatory activity without the pigmentation effects of the full hormone. It is categorized here as immune because the research concerns inflammatory signaling rather than tissue repair.

Commonly reported dosing (10 mg vial)

Reconstituted with 3 mL → 3.333 mg/mL.

Phase	Dose	Volume	U-100 units
Starting	200 mcg	0.06 mL	6
Standard	500 mcg	0.15 mL	15

Frequency: Once daily, subcutaneous · Half-life: Not well characterized in humans

Open in calculator

Commonly reported dose escalation

Weeks	Dose	Volume	U-100 units
Weeks 1-1	200 mcg	0.06 mL	6
Weeks 2-2	300 mcg	0.09 mL	9
Weeks 3-3	400 mcg	0.12 mL	12
Week 4+	500 mcg	0.15 mL	15

Higher steps may need a larger vial or more than one draw. Escalation schedules vary; dosing decisions belong to a licensed clinician.

Commonly reported reconstitution steps

Vials are usually brought to room temperature (about 15-20 minutes) first.
3 mL of bacteriostatic water is added slowly down the inside wall of the 10 mg vial.
The vial is swirled gently until clear, not shaken.
This gives 3.33 mg/mL. Mixed vials are typically labeled with the date and refrigerated.

Storage

Before mixing: Sealed vials are commonly stored refrigerated (2-8 °C) and protected from light, or frozen (about -20 °C) for long-term storage.

After mixing: Reconstituted solution is commonly kept refrigerated (2-8 °C), protected from light, and not frozen.

Commonly used within 28 days of mixing.

How it works

In cell and rodent studies KPV is taken up by the PepT1 transporter in intestinal epithelial and immune cells and is associated with reduced NF-κB and MAP-kinase signaling and lower pro-inflammatory cytokine output.

Researched for

Studied in mouse models of colitis, including oral and nanoparticle-delivered forms.
Investigated for effects on inflammatory signaling in epithelial and immune cells.
Explored in skin-inflammation research.

Notes

Evidence is preclinical; no completed human efficacy trials are known, so the injectable figures here come from peptide-protocol charts rather than clinical studies.
Much of the colitis research used oral or colon-targeted delivery rather than subcutaneous injection.